While a significant increase in KLK-3 levels can be concerning, it is not definitive for diagnosing prostate cancer, as various benign conditions can also cause KLK-3 elevation, However, Naringin treatment attenuated the surge in KLK3 levels, suggesting its role in modulating inflammatory responses and proteolytic activity. The gene discussed is KLK3; the disease is prostate cancer.